PMID- 16860997
OWN - NLM
STAT- MEDLINE
DCOM- 20070123
LR  - 20061114
IS  - 1040-8428 (Print)
IS  - 1040-8428 (Linking)
VI  - 60
IP  - 3
DP  - 2006 Dec
TI  - Kinase inhibitors in the treatment of renal cell carcinoma.
PG  - 216-26
AB  - Immunotherapy confers a small but significant overall survival advantage in 
      metastatic renal cell carcinoma (RCC) but a need exists to develop more effective 
      systemic therapies. Angiogenesis has a key role in the pathophysiology of renal 
      cell carcinoma and vascular endothelial growth factor (VEGF) is an important 
      mediator of this process. Sunitinib, sorafenib and axitinib are new agents which 
      belong to a class of drugs called kinase inhibitors and inhibit the VEGF, 
      platelet-derived growth factor (PDGF) and c-KIT receptor tyrosine kinases. 
      Temsirolimus inhibits the mammalian target of rapamycin (mTOR). All these agents 
      have shown significant activity with manageable toxicity in metastatic RCC in 
      phase 2 studies in patients generally pretreated with immunotherapy, whilst 
      prolonged progression-free survival in a phase 3 study has been reported with 
      sorafenib in comparison with placebo. Further phase 3 trials are recruiting and 
      the combination of kinase inhibitors with other therapies is under investigation.
FAU - Larkin, James M G
AU  - Larkin JM
AD  - Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 
      5PT, UK.
FAU - Eisen, Tim
AU  - Eisen T
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060724
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Carcinoma, Renal Cell/*drug therapy/enzymology
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/enzymology
MH  - Protein Kinase Inhibitors/*therapeutic use
RF  - 95
EDAT- 2006/07/25 09:00
MHDA- 2007/01/24 09:00
CRDT- 2006/07/25 09:00
PHST- 2005/10/30 00:00 [received]
PHST- 2006/04/30 00:00 [revised]
PHST- 2006/06/15 00:00 [accepted]
PHST- 2006/07/25 09:00 [pubmed]
PHST- 2007/01/24 09:00 [medline]
PHST- 2006/07/25 09:00 [entrez]
AID - S1040-8428(06)00117-X [pii]
AID - 10.1016/j.critrevonc.2006.06.008 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2006 Dec;60(3):216-26. doi: 
      10.1016/j.critrevonc.2006.06.008. Epub 2006 Jul 24.